ロード中...

BCR: a new target in resistance mediated by BCR/ABL-315I?

Targeting BCR/ABL with Tyrosine kinase inhibitors (TKIs) is a proven concept for the treatment of Philadelphia chromosome-positive (Ph+) leukemias but the “gatekeeper” mutation T315I confers resistance against all approved TKIs, with the only exception of ponatinib, a multi-targeted kinase inhibitor...

詳細記述

保存先:
書誌詳細
出版年:Genes Cancer
主要な著者: Haberbosch, Isabella, Rafiei, Anahita, Oancea, Claudia, Ottmann, Gerhart Oliver, Ruthardt, Martin, Mian, Afsar Ali
フォーマット: Artigo
言語:Inglês
出版事項: Impact Journals LLC 2016
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4773704/
https://ncbi.nlm.nih.gov/pubmed/27014420
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!